Menu Search
Equities

Optiscan Imaging Ltd

O5S:BER

Optiscan Imaging Ltd

Actions
  • Price (EUR)0.132
  • Today's Change-0.009 / -6.38%
  • Shares traded4.00k
  • 1 Year change+196.63%
  • Beta--
Data delayed at least 15 minutes, as of Jul 05 2024 07:08 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Optiscan Imaging Limited is an Australia-based company, which is engaged in the development, manufacturing and commercialization of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. The Company’s technology enables real-time, non-destructive, three-dimensional (3D), in-vivo imaging at the single-cell level. It provides real-time microscopic imaging tools to healthcare providers and researchers to enable the early detection and management of disease. Its InVivage device is an intra-oral digital microscope that offers the power of single-cell oral imaging at your fingertips in the palm of your hand. Its ViewnVivo offers single-cell level live imaging, providing biological system insights and enabling users to see life connected. Developed with its patented confocal imaging technology, ViewnVivo is a miniaturized in vivo imaging device that offers single-cell 3D live microscopic imaging in the palm of your hand.

  • Revenue in AUD (TTM)1.68m
  • Net income in AUD-5.44m
  • Incorporated1997
  • Employees8.00
  • Location
    Optiscan Imaging Ltd16 Miles StreetMULGRAVE 3170AustraliaAUS
  • Phone+61 39538-3333
  • Fax+61 39562-7742
  • Websitehttps://www.optiscan.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.